Cargando…
Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
Purpose: In current radiotherapy (RT) planning and delivery, population-based dose-volume constraints are used to limit the risk of toxicity from incidental irradiation of organs at risks (OARs). However, weighing tradeoffs between target coverage and doses to OARs (or prioritizing different OARs) i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446040/ https://www.ncbi.nlm.nih.gov/pubmed/32216586 http://dx.doi.org/10.1080/0284186X.2020.1733654 |
_version_ | 1783574098633293824 |
---|---|
author | Rechner, Laura Ann Modiri, Arezoo Stick, Line Bjerregaard Maraldo, Maja V. Aznar, Marianne C. Rice, Stephanie R. Sawant, Amit Bentzen, Søren M. Vogelius, Ivan Richter Specht, Lena |
author_facet | Rechner, Laura Ann Modiri, Arezoo Stick, Line Bjerregaard Maraldo, Maja V. Aznar, Marianne C. Rice, Stephanie R. Sawant, Amit Bentzen, Søren M. Vogelius, Ivan Richter Specht, Lena |
author_sort | Rechner, Laura Ann |
collection | PubMed |
description | Purpose: In current radiotherapy (RT) planning and delivery, population-based dose-volume constraints are used to limit the risk of toxicity from incidental irradiation of organs at risks (OARs). However, weighing tradeoffs between target coverage and doses to OARs (or prioritizing different OARs) in a quantitative way for each patient is challenging. We introduce a novel RT planning approach for patients with mediastinal Hodgkin lymphoma (HL) that aims to maximize overall outcome for each patient by optimizing on tumor control and mortality from late effects simultaneously. Material and Methods: We retrospectively analyzed 34 HL patients treated with conformal RT (3DCRT). We used published data to model recurrence and radiation-induced mortality from coronary heart disease and secondary lung and breast cancers. Patient-specific doses to the heart, lung, breast, and target were incorporated in the models as well as age, sex, and cardiac risk factors (CRFs). A preliminary plan of candidate beams was created for each patient in a commercial treatment planning system. From these candidate beams, outcome-optimized (O-OPT) plans for each patient were created with an in-house optimization code that minimized the individual risk of recurrence and mortality from late effects. O-OPT plans were compared to VMAT plans and clinical 3DCRT plans. Results: O-OPT plans generally had the lowest risk, followed by the clinical 3DCRT plans, then the VMAT plans with the highest risk with median (maximum) total risk values of 4.9 (11.1), 5.1 (17.7), and 7.6 (20.3)%, respectively (no CRFs). Compared to clinical 3DCRT plans, O-OPT planning reduced the total risk by at least 1% for 9/34 cases assuming no CRFs and 11/34 cases assuming presence of CRFs. Conclusions: We developed an individualized, outcome-optimized planning technique for HL. Some of the resulting plans were substantially different from clinical plans. The results varied depending on how risk models were defined or prioritized. |
format | Online Article Text |
id | pubmed-7446040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-74460402020-09-14 Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study Rechner, Laura Ann Modiri, Arezoo Stick, Line Bjerregaard Maraldo, Maja V. Aznar, Marianne C. Rice, Stephanie R. Sawant, Amit Bentzen, Søren M. Vogelius, Ivan Richter Specht, Lena Acta Oncol Original Articles: Radiotherapy and Radiobiology Purpose: In current radiotherapy (RT) planning and delivery, population-based dose-volume constraints are used to limit the risk of toxicity from incidental irradiation of organs at risks (OARs). However, weighing tradeoffs between target coverage and doses to OARs (or prioritizing different OARs) in a quantitative way for each patient is challenging. We introduce a novel RT planning approach for patients with mediastinal Hodgkin lymphoma (HL) that aims to maximize overall outcome for each patient by optimizing on tumor control and mortality from late effects simultaneously. Material and Methods: We retrospectively analyzed 34 HL patients treated with conformal RT (3DCRT). We used published data to model recurrence and radiation-induced mortality from coronary heart disease and secondary lung and breast cancers. Patient-specific doses to the heart, lung, breast, and target were incorporated in the models as well as age, sex, and cardiac risk factors (CRFs). A preliminary plan of candidate beams was created for each patient in a commercial treatment planning system. From these candidate beams, outcome-optimized (O-OPT) plans for each patient were created with an in-house optimization code that minimized the individual risk of recurrence and mortality from late effects. O-OPT plans were compared to VMAT plans and clinical 3DCRT plans. Results: O-OPT plans generally had the lowest risk, followed by the clinical 3DCRT plans, then the VMAT plans with the highest risk with median (maximum) total risk values of 4.9 (11.1), 5.1 (17.7), and 7.6 (20.3)%, respectively (no CRFs). Compared to clinical 3DCRT plans, O-OPT planning reduced the total risk by at least 1% for 9/34 cases assuming no CRFs and 11/34 cases assuming presence of CRFs. Conclusions: We developed an individualized, outcome-optimized planning technique for HL. Some of the resulting plans were substantially different from clinical plans. The results varied depending on how risk models were defined or prioritized. Taylor & Francis 2020-03-27 /pmc/articles/PMC7446040/ /pubmed/32216586 http://dx.doi.org/10.1080/0284186X.2020.1733654 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles: Radiotherapy and Radiobiology Rechner, Laura Ann Modiri, Arezoo Stick, Line Bjerregaard Maraldo, Maja V. Aznar, Marianne C. Rice, Stephanie R. Sawant, Amit Bentzen, Søren M. Vogelius, Ivan Richter Specht, Lena Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study |
title | Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study |
title_full | Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study |
title_fullStr | Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study |
title_full_unstemmed | Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study |
title_short | Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study |
title_sort | biological optimization for mediastinal lymphoma radiotherapy – a preliminary study |
topic | Original Articles: Radiotherapy and Radiobiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446040/ https://www.ncbi.nlm.nih.gov/pubmed/32216586 http://dx.doi.org/10.1080/0284186X.2020.1733654 |
work_keys_str_mv | AT rechnerlauraann biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy AT modiriarezoo biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy AT sticklinebjerregaard biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy AT maraldomajav biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy AT aznarmariannec biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy AT ricestephanier biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy AT sawantamit biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy AT bentzensørenm biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy AT vogeliusivanrichter biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy AT spechtlena biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy |